Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 0
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
Achiko AG engages in developing disruptive diagnostic solutions in Indonesia and internationally. The company's lead product is AptameX, a rapid test that uses DNA aptamers instead of antigens to detect the SARS-CoV-2 virus. It also offers Teman Sehat, a mobile check-in and passport application. In addition, the company provides secure payment solutions for game publishers and application developers to accept various payment methods for digital contents and goods under the Mimopay brand, as well as develops game software. Achiko AG was incorporated in 2018 and is headquartered in Zurich, Switzerland.
